SLN
SLN clinical trials: Silence Therapeutics plc
Every trial on ClinicalTrials.gov where Silence Therapeutics plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SLN on the catalyst calendar · SLN registry changes
- Primary completion Sep 2026Sponsor estimatePhase 1/Phase 2NCT05499013Study to Assess SLN124 in Patients With Polycythemia VeraSilence Therapeutics plc · Polycythemia VeraActive, not recruitingSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2024ActualPhase 2NCT05537571Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsSilence Therapeutics plc · Cardiovascular DiseasesCompletedSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2023ActualPhase 1NCT04606602Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)Silence Therapeutics plc · HyperlipidemiasCompletedSLNLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2023ActualPhase 1NCT04718844A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With...Silence Therapeutics plc · Non-transfusion-dependent ThalassemiaCompletedSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 23, 2021ActualEarly Phase 1NCT04559971A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy VolunteersSilence Therapeutics plc · Healthy VolunteersCompletedSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2021Sponsor estimatePhase 1NCT04176653Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124Silence Therapeutics plc · Non-transfusion-dependent ThalassemiaWithdrawnSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2015ActualPhase 1/Phase 2NCT01808638Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)Silence Therapeutics GmbH · Carcinoma, Pancreatic DuctalCompletedSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2012ActualPhase 1NCT00938574Study With Atu027 in Patients With Advanced Solid CancerSilence Therapeutics GmbH · Advanced Solid TumorsCompletedSLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner